CGTX
Cognition Therapeutics Inc
0.9251$
+3.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -9.3% | +10.5% | -11.5% | -19.8% | +9.6% | -22.3% | -16.5% | +121.2% | +11.5% | -25.3% | +7.6% | |
| – | -5.0% | +10.9% | -11.6% | -20.0% | +10.2% | -22.6% | -16.7% | +125.1% | +11.9% | -25.4% | +6.9% | |
| – | -9.2% | +15.9% | -17.7% | -22.9% | +13.6% | -34.3% | -34.6% | +270.7% | -7.1% | -15.9% | +9.3% | |
| – | -9.2% | +15.9% | -17.7% | -22.9% | +13.6% | -34.3% | -34.6% | +270.7% | -7.1% | -15.9% | +9.3% | |
| – | -21.8% | -32.8% | +259.9% | +8.7% | -20.3% | +77.9% | +31.5% | -69.8% | +422.3% | -63.1% | -19.3% | |
| – | +8.6% | -6.5% | +13.7% | +15.3% | -12.3% | -2.2% | +12.1% | -45.5% | +105.6% | -55.9% | -5.7% | |
| – | +23.6% | -6.5% | +14.9% | +16.3% | -12.3% | -1.7% | +12.9% | -46.2% | +109.3% | -56.5% | -10.0% | |
| – | +317.4% | -24.0% | -32.4% | -49.1% | +151.1% | -24.8% | -32.7% | -29.7% | +163.7% | -34.8% | -69.2% | |
| – | +29.2% | -28.6% | +15.0% | -37.5% | +4.7% | -8.2% | -57.7% | +7.3% | +35.3% | +244.1% | -82.5% | |
| – | -15.4% | +17.9% | -20.3% | -37.1% | +29.5% | -34.6% | -42.7% | +419.7% | -6.2% | -12.7% | +10.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.4% | +9.6% | +18.8% | +0.9% | +14.9% | +33.2% | +3.0% | +22.4% | +14.1% | +0.3% | +1.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.